

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/74	A1	(11) International Publication Number: WO 98/02751 (43) International Publication Date: 22 January 1998 (22.01.98)
(21) International Application Number: PCT/GB97/01880 (22) International Filing Date: 11 July 1997 (11.07.97) (30) Priority Data: 9614615.4 11 July 1996 (11.07.96) GB (71) Applicants (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; 2 South Parks Road, Oxford OX1 3UB (GB). THE UNIVERSITY OF READING [GB/GB]; Whiteknights, Reading RG6 6AH (GB). OXFORD BROOKES UNIVERSITY [GB/GB]; Gipsy Lane, Headington, Oxford OX3 0BP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): GROOME, Nigel, Patrick [GB/GB]; 35 Kennington Road, Kennington, Oxford OX1 5PB (GB). KNIGHT, Philip, Gerald [GB/GB]; 92 Hamilton Road, Reading RG1 5RD (GB). LEDGER, William, Leigh [GB/GB]; 36 Oxford Road, Old Marston, Oxford OX3 0PQ (GB). REDMAN, Christopher, Willard, George [GB/GB]; 59 Southmoor Road, Oxford OX2 6RF (GB). MUTTUKRISHNA, Shanthi [LK/GB]; 3 Falstaff Avenue, Earley, Reading RG6 5TW (GB).		(74) Agent: PRIVETT, Kathryn, L.; Stevens, Hewlett & Perkins, Fleet Street, 1 Serjeants' Inn, London EC4Y 1LL (GB). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: DIAGNOSIS OF PRE-ECLAMPSIA (57) Abstract <p>A method for diagnosis of pre-eclampsia is disclosed, which comprises measuring the hormone inhibin A in a biological sample such as maternal serum. The method allows non-invasive, early diagnosis and can be used to predict the onset of secondary symptoms.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

DIAGNOSIS OF PRE-ECLAMPSIA

This invention relates to detection of pre-eclampsia. In particular, it relates to early diagnosis of pre-eclampsia by detecting
5 elevated levels of the hormone inhibin A.

Pre-eclampsia, otherwise known as gestational proteinuric hypertension (GPH) is a multisystem disease of pregnancy of unknown cause. The maternal syndrome is characterised by various abnormalities: increased blood pressure, oedema, proteinuria and abnormal clotting, liver
10 and renal function. The cause of pre-eclampsia is believed to lie in the placenta and there is evidence for a circulating endothelial cell "toxic" factor which is most likely to originate from the syncytiotrophoblast. The syncytiotrophoblast provides the surface of contact between the placenta and the maternal blood and is a multi-nucleated syncytium with an
15 extensive microvillous brush border.

Pre-eclampsia is a relatively common condition, occurring in approximately one in ten pregnant women. Around 10% of cases will be severe. In severe cases, early delivery may be necessary and there is therefore the risk of the child being handicapped. Pre-eclampsia also
20 remains a danger to the lives of both babies and mothers.

The symptoms of pre-eclampsia described above are generally detectable from around 28 weeks up to full term and are not normally apparent before 24 weeks. The conventional tests are for kidney failure by measuring urea in the blood or protein in the urine, and for
25 increased maternal blood pressure. There are some other indicators of pre-eclampsia, including hormonal ones. However, none of these tests can predict the on-set of pre-eclampsia more than a few days in advance of secondary symptoms becoming fully apparent.

If pre-eclampsia could be detected earlier, before clinical
30 symptoms arise, it would be possible to intervene in affected pregnancies

e.g. by treating with anti-hypersensitive drugs, increasing monitoring and foetal surveillance and thereby improve foetal and maternal outcome.

Thus, there is a need for a new test for pre-eclampsia and in particular a test that can predict the on-set of the secondary symptoms of pre-eclampsia earlier than existing tests. Other tests are routinely carried out during pregnancy e.g. spina bifida is tested for at 16 weeks. If pre-eclampsia could be tested for several weeks in advance of the possible on-set of symptoms, more time would be available for treatment to avoid the possibility of serious problems arising.

It has now been discovered that the hormone inhibin A is significantly increased in cases of pre-eclampsia compared to normal pregnancies. Before secondary symptoms of pre-eclampsia are detectable, a group of patients who went on to develop pre-eclampsia showed a higher mean inhibin A level than a second group who did not go on to develop pre-eclampsia.

Inhibin A is a member of the family of inhibins which are heterodimeric proteins consisting of $\alpha\beta_A$ (inhibin A) and $\alpha\beta_B$ (inhibin B) subunits. The term "inhibin A" as used herein refers to the dimeric protein, which is the biologically active form of inhibin A. The two protein subunits are joined together by disulphide bonds. Inhibin A is produced mainly by the ovaries and has an endocrine role in inhibiting pituitary follicle stimulating hormone (FSH) production. In pregnancy, circulating levels of inhibin A are increased with the placenta being the major source (Muttukrishna et al 1995). In contrast, inhibin B levels are not elevated in either control or pre-eclampsia pregnancies.

EP 185 034 discloses one dimeric form of inhibin, which it identifies in terms of molecular weight, subunit structure and other properties. The sizes given are $14\text{kD}\pm 2\text{kD}$ and 44kD . Later research suggests that the primary active form of inhibin A in biological fluids is a 32kD molecule formed by a 12kD β_A and 20kD subunit. The 32kD inhibin

is the mature form produced by post-translational processing of precursor forms of molecular weight 65kD and 56kD. Immunoreactive α monomer also circulates in the body. The various different circulating inhibin proteins are often together referred to as "inhibin forms".

5 It has also been discovered that maternal peripheral serum concentrations of the related hormones pro alpha C and activin A, when measured as total activin A, are significantly elevated in pre-eclampsia compared to normal maternal serum. Activins are homodimers consisting of $\beta_A\beta_A$ (activin A), $\beta_A\beta_B$ (activin AB) and $\beta_B\beta_B$ (activin B) subunits linked by
10 disulphide bridges. Activin A occurs naturally in free form and in bound form, bound to a protein called follistatin. "Total" activin A refers to both activin A whether free or bound. Pro alpha C is a part of the α subunit of inhibin A which is not present in the biologically active dimer. Serum human chorionic gonadotrophin (hCG) concentrations are also significantly
15 higher in pre-eclampsia compared to normal pregnancy serum.

Khalil et al 1995 and Petraglia et al 1995 discuss hormone levels during normal and abnormal pregnancies but do not describe or suggest any possibility of a test for pre-eclampsia.

The present invention provides in one aspect a method of
20 diagnosis of pre-eclampsia which method comprises measuring inhibin A in a biological sample.

Diagnosis according to the invention includes predictive diagnosis of pre-eclampsia, that is a prediction that the secondary symptoms of pre-eclampsia such as high blood pressure will occur.

25 Preferably, the sample is a maternal body fluid. The sample may be a serum or plasma sample from the maternal blood. Alternatively, it may be for example an amniotic fluid sample.

In another aspect, the invention provides the use of inhibin A levels as an indicator of pre-eclampsia.

The invention may further comprise measuring the level of other proteins, which may be hormones and the use of other such proteins together with inhibin A as indicators of pre-eclampsia. The additional proteins measured may be one or more of the hormones activin A, pro
5 alpha C and hCG. Where activin A is measured, this is preferably total activin A.

The way in which measurement of inhibin A is carried out is not material to the invention. Recently developed specific and sensitive assays for inhibin A are described by Groome et al 1994; and Muttukrishna
10 et al 1994. The presently preferred manner for measuring inhibin A in a biological sample uses one antibody specific for the alpha-subunit of inhibin A and a second antibody specific for the beta-subunit of inhibin A.

In yet another aspect, the invention provides the use of an antibody system specific for inhibin A in a test for pre-eclampsia.

15 In accordance with the invention, levels of all molecular forms of dimeric inhibin A are preferably measured, irrespective of molecular size. However, the measurement of specifically the mature 32kD form of the protein may be sufficient for the purposes of the invention.

In accordance with the present invention, it has been
20 demonstrated that inhibin A levels are significantly increased in pre-eclamptic pregnancies over normal pregnancies. Not only that, it has also been found that there is no overlap in inhibin A levels between pre-eclamptic and normal pregnancies. Furthermore, it has been demonstrated that at an early stage in gestation, before the secondary
25 symptoms of pre-eclampsia are normally detectable, a significantly higher inhibin A level is detectable in a group of patients who go on to develop pre-eclampsia compared to a control group of individuals who do not have a pre-eclamptic pregnancy.

A clinically useful screening test for women at risk of pre-
30 eclampsia has not previously existed. Detection of patients at high risk of

pre-eclampsia before the disease develops will allow increased surveillance, monitoring of foetal growth and well-being and placental function. It may also lead to new methods of intervention to stabilise blood pressure and renal function and possibly reduce the severity of the disease. Any intervention which can prolong pregnancy safely will reduce the burden of prematurity which remains one of the major causes of foetal mortality and neonatal and childhood handicap.

In the attached figures:

Figure 1 shows assay validation curves constructed from levels of inhibin A, activin A and pro alpha C in maternal samples from pre-eclamptic and control pregnancies;

Figure 2 shows individual concentrations of inhibin A, activin A, pro alpha C and hCG in individual maternal serum samples in pre-eclamptic and control pregnancies; and

Figure 3 shows a profile of inhibin A and activin A immunoreactivity after FPLC gel-permeation chromatography of control and pre-eclampsia maternal serum.

Figure 4 shows maternal serum inhibin A concentrations in normal and pre-eclamptic pregnancies at different stages of pregnancy. Numerical values are given in Table 1.

Figure 5 shows maternal serum inhibin A concentrations in individuals at 16 weeks gestation, for a group of patients who go on to develop pre-eclampsia and for a second group who do not develop pre-eclampsia.

The invention will now be further described in the following examples.

EXAMPLES

MATERIALS AND METHODS

Sample Collection

5 Blood samples obtained from 20 pre-eclamptic patients and
20 normal gestational age matched control pregnant women were used for
the measurement of the hormones. The samples were obtained at the pre-
eclampsia clinic and the antenatal clinic respectively, and had been
collected as part of other studies for which patients have given informed
10 consent. Serum was separated by centrifugation and stored at -20°C.

 Serum samples collected at 16 weeks gestation for
pregnancy screening were analysed. Serum from 15 pregnant women who
developed pre-eclampsia later in pregnancy and 54 matched control
pregnant women who were normal throughout pregnancy were analysed.

15

Fractionation of samples by chromatography (FPLC)

 Serum samples pooled from pre-eclamptic patients (n=20)
and control pregnant women (n=20) were fractionated by gel permeation
chromatography. 100µl serum samples were applied to a fast protein
20 liquid chromatography (FPLC) column (Superose 12, Pharmacia Ltd.,
Milton Keynes, Bucks, UK) which was equilibrated and eluted with
phosphate-buffered saline (pH 7.4) containing 0.1% (w/v) polypep (Sigma)
and 0.05% (w/v) sodium azide at a flow rate of 0.5ml/minute. Fractions
were collected for the measurement of inhibin A, pro alpha C and activin A.
25 For calibration purposes, the retention times of the following proteins
were determined: α_2 -macroglobulin (750kDa); alcohol dehydrogenase
(150kDa); bovine serum albumin (66kDa); recombinant inhibin A (32kDa);
recombinant activin A (24kDa) and cytochrome C (12.5kDa).

30

Hormone Assays

Inhibin A Serum and FPLC fraction concentrations of dimeric inhibin A were measured in duplicate 5µl and 25µl aliquots respectively as described below and elsewhere (Muttukrishna et al, 1994). The mean intra and inter
5 assay variations were 4.3 % and 5.1% respectively. Minimum detection limit of the assay for human recombinant inhibin A (kindly provided by Dr.M.Rose, NIBS, UK) was 2pg/ml.

Inhibin B Serum concentrations of dimeric inhibin B were measured in duplicate 50µl using an enzyme immunoassay as described in detail
10 elsewhere (Groome et al, 1996) with some modifications. Minimum detection limit of the assay for human recombinant inhibin B was 30pg/ml. The mean intra and inter assay variations were 6.2% and 7.2% respectively.

Pro alpha C Serum and FPLC fraction concentrations of pro alpha C were
15 measured in duplicate 25µl and 50µl aliquots respectively as described before (Groome et al, 1995) with some modifications. Minimum detection limit of the assay for pro alpha C standard (Prof. N P Groome) was 5pg/ml. The mean intra and inter assay variations are 6.8% and 8.6% respectively.

Activin A Serum and FPLC fraction concentrations of dimeric activin A
20 were measured using an EIA specific for 'total' activin A as described below and elsewhere (Knight et al, 1996). The mean intra and inter assay variations were 6.5% and 7.7% respectively. The minimum detection limit of the assay for human recombinant activin A (Genentech, USA) was
25 50pg/ml.

hCG Serum concentrations of hCG were measured using immulite-chemiluminescent assay kits (Diagnostic Products Ltd.). All samples were assayed in the same assay and the mean intra assay variation was <10%.

Two-site enzyme immunoassay for dimeric inhibin-A**Coating of plates with E4 capture antibody**

Monoclonal antibodies against the β_A subunit of human inhibin were covalently linked to 96-well hydrazide plates (UniSyn Technologies Inc., Tustin, CA, USA) through their carbohydrate moieties. Immediately before use, plates were washed (10 cycles) with enzyme immunoassay wash buffer (0.05% Tween 20 (Sigma, UK) in 0.05 M Tris buffer pH 7.5) on a microplate washer and dried by inversion onto paper towelling.

10

Preparation and oxidation of standards and samples

Recombinant human inhibin A or purified 32 kDa bovine inhibin used as reference preparations were serially diluted in enzyme immunoassay diluent alone [10% (w/v) bovine serum albumin (BSA), 5% (v/v) mouse serum (Sigma), 5% (v/v) Triton X-100, 0.15 M sodium chloride in 0.1 M Tris-HCl buffer pH 7.5] or in enzyme immunoassay diluent mixed with an equal volume of pooled human post-menopausal serum (PMS). Serum samples were diluted as appropriate in enzyme immunoassay diluent (normally a 1:1 dilution of normal cycle serum; 1:10 dilution of hyperstimulated serum; 1:2000 dilution of human follicular fluid). Dilutions of standards and samples were made in 2.5 ml disposable plastic tubes. Pre-assay oxidation of standards and samples was then carried out by adding freshly prepared hydrogen peroxide solution (10% v/v: Sigma) to give a final concentration of 2% (v/v). Tubes were mixed thoroughly and incubated for 30 min at room temperature before transferring 100 μ l aliquots to E4-coated plates.

20

25

Enzyme immunoassay procedure

Plates were placed in a humidity chamber and incubated at 4° on a rocking platform. After overnight incubation, the plates were

30

washed (10 cycles) before adding to each well 50 μ l of alkaline phosphate-conjugated α subunit monoclonal antibody [R, F(ab); 1:32 000 dilution]. After mixing for 2 hours at room temperature on a microplate shaker, plates were washed extensively (18 cycles) with the final three wash cycles made using wash buffer without Tween 20. Quantification of bound alkaline phosphatase was made using a commercially available enzyme immunoassay amplification kit (Immuno Select ELISA Amplification System, Gibco BRL, Uxbridge, UK) which was used according to the supplier's instructions. To minimize the risk of temperature-dependent variation in signal generation, both incubation steps were performed at ambient temperature. After incubation with "kit substrate solution" (50 μ l/well) for one hour on a microplate shaker, 50 μ l of "kit amplifier solution" was added to each well. The amplification reaction was stopped before blank wells began to show significant colour development by adding 50 μ l of 0.3 M sulphuric acid (normally stopped after ~ one hour). Absorbance of 492 nm was read on an enzyme immunoassay plate reader and data processed by immunoassay curve-fitting software (Riacalc, Pharmacia-LKB, Milton Keynes, UK).

20 **Activin A enzyme immunoassay**

Activin A concentrations were measured using a 2-site EIA. Briefly, standards (recombinant human activin A) and samples were diluted as appropriate in PBS containing 10% (w/v) bovine serum albumin (BSA) and 0.1% (w/v) sodium azide. 125 μ l volumes of diluted samples and standards were transferred to 1.5ml microfuge tubes and mixed with an equal volume (125 μ l) of distilled water containing 20% (w/v) sodium dodecyl sulphate (SDS). After a 10 min incubation at 90-95°C tubes were cooled before adding 20 μ l hydrogen peroxide solution (30% v/v; Sigma). After a further 10 min incubation at room temperature, duplicate 100 μ l aliquots of denatured and oxidized samples/standards were transferred to

E4 antibody-coated microtitre plates containing 25 μ l EIA plate buffer/well (0.1M Tris-HCl, 0.15M NaCl, 10% (w/v) BSA, 5% (v/v) Triton X-100 and 0.1% (w/v) sodium azide; pH 7.5). After adding to each well 25 μ l EIA plate buffer containing ~35ng biotinylated E4 monoclonal antibody, plates
5 were incubated overnight in a humidified box at ambient temperature. After washing (15 cycles) with EIA wash buffer (0.05M Tris-HCl, 0.15M NaCl, 0.05% v/v Tween-20, 0.05% v/v sodium azide, pH 7.5), 50 μ l alkaline phosphatase-conjugated Extravidin (1:10,000 v/v; Sigma) was added and plates were incubated for 2 hours at room temperature in a humidified box.
10 Plates were washed thoroughly (18 cycles) and bound alkaline phosphatase quantitated using a commercially available ELISA amplification kit (Immunoselect ELISA Amplification system, Gibco-BRL, Uxbridge, UK) according to the supplier's instructions. The limit of detection was 10 pg/well and intra- and inter-assay coefficients of variation
15 (CV) were 5.0 and 9.1% respectively. Cross-reaction of rh inhibin A, inhibin B and activin B were <0.5%. Cross-reaction of rh follistatin-288 (gift from NIDDK) and bovine pro- α C were <0.1%. Neither follistatin (500ng/ml) or human α 2 macroglobulin (α 2M; 100 μ g/ml; Calbiochem) interfered in the assay and recovery of activin A standard added to human serum samples
20 was 96 \pm 5% (n=12 samples).

Statistical Analysis

Unpaired student's t-tests were carried out to compare the concentrations of hormones of control and pre-eclamptic patients.
25 Spearman correlation analyses were carried out to investigate the relationship between hormones, platelet counts and blood pressure in pre-eclampsia. All statistical analysis were carried out using Graph Pad Prism statistical package using 95% confidence interval limit.

RESULTS

A) For Serum samples taken between 20 and 38 weeks gestation (mean 29 weeks)

Behaviour of normal and pre-eclamptic pregnancy sera in the EIAs

5 Serial dilutions of control and pre-eclamptic serum gave response curves in the inhibin A (figure 1a), pro alpha C (figure 1c) and activin A (figure 1b) enzyme immunoassays which were parallel to that for the human recombinant inhibin A standard, human pro alpha C standard and human inhibin B standard respectively. Recovery of exogenous

10 human recombinant inhibin A (3.8pg/well), human recombinant activin A (100pg/well) and pro alpha C (5pg/well) added before assay to aliquots of control pregnancy serum ($105\pm6\%$, $113\pm13\%$, $98\pm3.2\%$ respectively) and pre-eclampsia serum ($94.9\pm6.7\%$, $122.4\pm19.2\%$, $105\pm10.5\%$ respectively) were almost quantitative.

15 Serum concentration of inhibin A, pro alpha C and activin A (figure 2)

 Maternal serum concentrations of inhibin A (figure 2a) were increased by ~8 fold ($P<0.001$) in pre-eclampsia compared to control pregnancies. Peripheral concentrations of pro alpha C (figure 2c) were almost 3 fold ($P<0.001$) enhanced and levels of activin A (figure 2b) were

20 significantly (~9 fold, $P<0.001$) elevated in pre-eclampsia.

Serum concentrations of hCG

 Peripheral serum concentration of hCG was ~4 fold higher ($P<0.001$) in pre-eclampsia (59.05 ± 9.27 IU/ml) compared to control pregnancy (16.3 ± 1.84 IU/ml) maternal serum (figure 2d).

25 Gel permeation chromatography (figure 3)

 Measurement of inhibin A and activin A in the chromatographic profiles of pooled pre-eclamptic and control pregnancy sera detects only one major peak of inhibin A (32kDa) and activin A (>100kDa) in the enzyme immunoassays. Levels of pro alpha C were just

30 above the detection limit in the pre-eclamptic serum fractions and

undetectable in the control serum chromatographic fractions. Inhibin A co-eluted with the human recombinant inhibin A(32kDa) and represents the fully processed mature form of inhibin A. However, activin A immunoreactivity eluted with an apparent molecular weight >100kDa
5 suggesting that almost all activin A in circulation is bound to activin binding proteins with no detectable 'free' activin A corresponding to the elution position of human recombinant activin A (~25kDa).

B) For serum samples at 16 weeks gestation

10 Measurement of serum inhibin A in samples taken at 16 weeks gestation indicates a significantly higher mean inhibin A concentration for a group of individuals who went on to suffer pre-eclampsia (327 ± 27.15 pg/ml), compared to a control group who did not develop pre-eclampsia (197.67 ± 23.77 pg/ml) ($P=0.0097$). Results are
15 shown in Figure 5.

REFERENCES

- Groome, N.P., Illingworth P.J., O'Brien, M., Cooke, I., Ganesan, T.S.,
20 Baird, D.T. and McNeilly, A.S., (1994) Clinical Endocrinology, **40**, 717-723.
- Groome, N.P., Illingworth, P.J., O'Brien, M., Priddle, J., Weaver, K. and McNeilly, A.S. (1995) Journal of Clinical Endocrinology and Metabolism, **80**, 2926-2932.
- 25 Groome, N.P., Illingworth, P.J., O'Brien, M., Pai, R., Rodger, F.E., Mather, J., and McNeilly, A.S. (1996) Journal of Clinical Endocrinology and Metabolism (in press).
- Khalil, A., Kaufmann, R. C., Wortsman, J., Winters, S.J. and Huffmann, D.G. (1995) Am.J.Obstet. Gynaecol. **172**, 1019-1025.

Knight, P.G., Muttukrishna S., and Groome N.P. (1996) *Journal of Endocrinology* **148**, 267-279.

Muttukrishna, S., Fowler, P.A., Groome, N.P., Mitchell, G.G., Robertson, W. R. and Knight, P.G., (1994) *Human Reproduction* **9**, 1634-1642.

Muttukrishna, S., George, L., Fowler, P.A., Groome, N.P., and Knight, P.G., (1995) *Clinical Endocrinology* **42**, 391-397..

Petraglia, F., Aguzzoli, L., Gallinelli, A., Florio, P., Zonca, M., Benedetto, C., and Woodruff, K. (1995) *Placenta* **16**, 447-454.

Figure Legends

Figure 1 Parallel response curves for serial dilutions of protein standard, pooled control pregnancy serum and pooled pre-eclampsia serum in the (a) inhibin A, (b) activin A and (c) pro alpha C enzyme immunoassays.

Values are means of duplicate determinations of absorbance.

Figure 2 Scatter plot of individual concentrations of a) inhibin A, b) activin A, c) pro alpha C and d) hCG in maternal serum in pre-eclampsia (n=20) and control pregnancy (n=20).

Figure 3 Profile of (a) inhibin A and (b) activin A immunoreactivity

measured by EIA after FPLC gel-permeation chromatography of 100µl samples of control or pre-eclampsia maternal serum. Values are mean ± SEM (n=3 separate fractionations). The elution positions of the following proteins are indicated: α₂-macroglobulin (Vo; 725kDa), alcohol dehydrogenase (AD; 150kDa) bovine serum albumin (BSA; 66kDa), recombinant human inhibin A (32kDa), human recombinant activin A (24kDa) and cytochrome C (12.5kDa).

Hormone Concentrations in Maternal Serum

Table 1

PRE-ECLAMPSIA

Gestational age (days)	Gestation (weeks)	parity	inhibin A (ng/ml)	activin A (ng/ml)	Pro alpha C (ng/ml)	hCG (IU/ml)
206	29	0+0	1.26	10.97	0.67	33.79
187	27	0+0	>10	74.52	2.02	152.08
217	31	0+0	2.50	44.94	1.24	58.64
198	28	0+0	5.12	75.20	0.53	10.37
206	29	0+0	1.40	24.35	1.72	70.92
184	26	0+0	2.40	>100	0.57	57.34
229	33	0+0	2.07	19.38	1.50	35.26
191	27	0+0	5.15	51.43	0.71	27.85
173	25	0+0	5.45	39.10	1.70	98.71
233	33	0+0	5.48	33.30	0.96	47.82
		Mean	3.43	41.47	1.16	59.28
		SEM	0.61	7.57	0.18	13.63
Gestational age (days)	Gestation (weeks)	parity	inhibin A (ng/ml)	activin A (ng/ml)	Pro alpha C (ng/ml)	
165	24	1+1	1.58	17.55	2.14	18.38
205	29	0+0	0.93	30.04	1.90	129.17
249	36	1+0	6.08	20.68	3.50	91.49
191	27	0+0	1.17	14.73	1.96	56.87
212	30	0+0	2.12	101.98	1.88	12.22
153	22	1+0	2.01	18.58	1.76	52.55
239	34	0+0	2.10	27.93	2.39	131.56
183	26	1+3	4.19	37.37	2.64	16.56
228	33	2+0	3.76	57.80	1.69	40.76
236	34	0+1	3.22	23.64	2.11	38.68
		Mean	2.72	35.03	2.20	58.82
		SEM	0.50	8.44	0.17	14.01
		Mean(n=20)	3.05	38.08	1.68	59.05
		SEM	0.38	5.46	0.17	9.28

Table 1 (cont.)

CONTROL


Gestational age (days)	Gestation (weeks)	parity	inhibin A (ng/ml)	activin A (ng/ml)	Pro alpha C (ng/ml)	hCG (IU/ml)
213	30	0+0	0.37	7.22	0.47	33.23
198	28	0+0	0.54	3.49	0.49	23.25
208	30	0+0	0.31	4.37	0.44	18.06
193	28	0+0	0.34	4.39	0.53	16.79
210	30	0+0	0.47	5.23	1.05	18.38
191	27	0+0	0.26	3.51	0.36	15.37
230	33	0+0	0.54	3.59	0.83	33.48
196	28	0+0	0.29	1.53	0.39	20.24
181	26	0+0	0.47	1.74	0.31	5.57
225	32	0+0	0.53	7.36	0.98	7.44
		Mean	0.41	4.24	0.58	19.18
		SEM	0.03	0.62	0.08	2.91
Gestational age (days)	Gestation (weeks)	parity	inhibin A (ng/ml)	activin A (ng/ml)	Pro alpha C (ng/ml)	hCG (IU/ml)
159	23	2+0	0.13	1.47		11.80
205	29	0+0	0.29	1.95	0.52	23.36
250	36	1+0	0.39	4.56	0.94	7.83
197	28	0+0	0.25	1.38	0.55	17.06
223	32	0+0	0.28	9.85	0.64	8.37
142	20	1+0	0.11	1.71		16.72
244	35	0+0	0.63	3.76	1.12	23.16
194	28	2+0	0.32	3.64	0.67	9.27
216	31	1+0	0.21	4.05		6.38
223	32	0+0	0.41	4.19	0.53	10.19
		Mean	0.30	3.66	0.71	13.41
		SEM	0.05	0.79	0.07	1.98
		Mean(n=20)	0.36	3.95	0.63	16.30
		SEM	0.03	0.49	0.06	1.84

CLAIMS

1. A method of diagnosis of pre-eclampsia which method comprises measuring inhibin A in a biological sample.
- 5 2. A method as claimed in claim 1, wherein the sample is from maternal blood.
3. A method as claimed in claim 1 or claim 2, wherein the inhibin A is measured by means of an immunoassay.
4. A method as claimed in any one claims 1 to 3, wherein the
10 method further comprises measuring the level of at least one additional protein.
5. A method as claimed in claim 4, wherein the additional protein is at least one hormone chosen from activin A, pro alpha C and hCG.
- 15 6. The use of inhibin A levels as an indicator of pre-eclampsia.
7. The use of an antibody system specific for inhibin A in a test for pre-eclampsia.


1/4

Fig.1.




2/4

Fig.2.



3/4

Fig.3.



4/4

Fig.4.





Fig.5.



INTERNATIONAL SEARCH REPORT

International Application No.

PL/GB 97/01880

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 701 131 A (JOHNSON & JOHNSON CLIN DIAG) 13 March 1996 see claims 1-10 ---	1-7
A	EP 0 359 274 A (ASPEN DIAGNOSTICS CORP) 21 March 1990 see claims 1-10 ---	1-7
A	WO 87 05702 A (BIOTECH AUSTRALIA PTY LTD ;UNIV MONASH (AU); PRINCE HENRYS HOSPITA) 24 September 1987 see claims 1-26 ---	1-7
P,A	US 5 545 616 A (WOODRUFF TERESA K) 13 August 1996 see claims 1,2,4,8 see column 8, line 29 - line 34 --- -/-	1-7



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

6 November 1997

Date of mailing of the international search report

21. 11. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Routledge, B

INTERNATIONAL SEARCH REPORT

International Application No.

PC/GB 97/01880

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CLINICAL CHEMISTRY, vol. 42, no. 8, 1996, page 1159-1167 XP002045969 see figure 6</p> <p>-----</p>	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PL 1/GB 97/01880

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0701131 A	13-03-96	AU 2848795 A CA 2155919 A FI 953830 A JP 9113508 A	29-02-96 14-02-96 14-02-96 02-05-97
EP 0359274 A	21-03-90	US 5079171 A AT 130437 T AU 623678 B AU 4131689 A CA 1338899 A DE 68924818 D DE 68924818 T ES 2079366 T JP 2115767 A JP 2597013 B	07-01-92 15-12-95 21-05-92 22-03-90 11-02-97 21-12-95 02-05-96 16-01-96 27-04-90 02-04-97
WO 8705702 A	24-09-87	AU 599373 B AU 7203687 A CA 1307736 A EP 0260306 A JP 63503086 T	19-07-90 09-10-87 22-09-92 23-03-88 10-11-88
US 5545616 A	13-08-96	NONE	